March 18, 2021 04:48 PM EDTUpdated 05:22 PM

Idera squelches any lingering enthusiasm as its lead TLR9 drug flunks PhIII — badly

More than 3 years ago, with its stock riding high, Idera $IDRA caused quite a stir at ESMO with its TLR9 drug and the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Idera squelch­es any lin­ger­ing en­thu­si­asm as its lead TLR9 drug flunks PhI­II — bad­ly